Pharmacological activation of the circadian component REV-ERB inhibits HIV-1 replication.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
06 08 2020
Historique:
received: 09 04 2020
accepted: 07 07 2020
entrez: 9 8 2020
pubmed: 9 8 2020
medline: 16 12 2020
Statut: epublish

Résumé

Human immunodeficiency virus 1 (HIV-1) is a life-threatening pathogen that still lacks a curative therapy or vaccine. Despite the reduction in AIDS-related deaths achieved by current antiretroviral therapies, drawbacks including drug resistance and the failure to eradicate infection highlight the need to identify new pathways to target the infection. Circadian rhythms are endogenous 24-h oscillations which regulate physiological processes including immune responses to infection, and there is an emerging role for the circadian components in regulating viral replication. The molecular clock consists of transcriptional/translational feedback loops that generate rhythms. In mammals, BMAL1 and CLOCK activate rhythmic transcription of genes including the nuclear receptor REV-ERBα, which represses BMAL1 and plays an essential role in sustaining a functional clock. We investigated whether REV-ERB activity regulates HIV-1 replication and found REV-ERB agonists inhibited HIV-1 promoter activity in cell lines, primary human CD4 T cells and macrophages, whilst antagonism or genetic disruption of REV-ERB increased promoter activity. The REV-ERB agonist SR9009 inhibited promoter activity of diverse HIV-subtypes and HIV-1 replication in primary T cells. This study shows a role for REV-ERB synthetic agonists to inhibit HIV-1 LTR promoter activity and viral replication, supporting a role for circadian clock components in regulating HIV-1 replication.

Identifiants

pubmed: 32764708
doi: 10.1038/s41598-020-70170-3
pii: 10.1038/s41598-020-70170-3
pmc: PMC7413328
doi:

Substances chimiques

Antiviral Agents 0
Pyrrolidines 0
Receptors, Thyroid Hormone 0
SR9009 0
Thiophenes 0
rev Gene Products, Human Immunodeficiency Virus 0
rev protein, Human Immunodeficiency Virus-1 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

13271

Subventions

Organisme : Medical Research Council
ID : G0400802
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0801976
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R022011/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : IA 200838/Z/16/Z
Pays : United Kingdom

Références

Takahashi, J. S. Transcriptional architecture of the mammalian circadian clock. Nat. Rev. Genet.18(3), 164–179 (2017).
pubmed: 27990019
Solt, L. A., Kojetin, D. J. & Burris, T. P. The REV-ERBs and RORs: molecular links between circadian rhythms and lipid homeostasis. Future Med. Chem.3(5), 623–638 (2011).
pubmed: 21526899 pmcid: 3134326
Curtis, A. M. et al. Circadian clock proteins and immunity. Immunity40(2), 178–186 (2014).
pubmed: 24560196
Scheiermann, C. et al. Clocking in to immunity. Nat. Rev. Immunol.18(7), 423–437 (2018).
pubmed: 29662121
Downton, P., Early, J. O., Gibbs, J. E. Circadian rhythms in adaptive immunity. Immunology (2019). https://doi.org/10.1111/imm.13167 .
doi: 10.1111/imm.13167 pubmed: 31837013
Edgar, R. S. et al. Cell autonomous regulation of herpes and influenza virus infection by the circadian clock. Proc. Natl. Acad. Sci. U S A113(36), 10085–10090 (2016).
pubmed: 27528682 pmcid: 5018795
Long, J. E. et al. Morning vaccination enhances antibody response over afternoon vaccination: a cluster-randomised trial. Vaccine34(24), 2679–2685 (2016).
pubmed: 27129425 pmcid: 4874947
Zhuang, X. et al. Interplay between circadian clock and viral infection. J. Mol. Med. (Berl)95(12), 1283–1289 (2017).
Mazzoccoli, G. et al. the circadian clock, the immune system, and viral infections: the intricate relationship between biological time and host-virus interaction. Pathogens9(2), 83 (2020).
pmcid: 7168639
Zhuang, X. et al. Daytime variation in hepatitis C virus replication kinetics following liver transplant. Wellcome Open Res.3, 96 (2018).
pubmed: 30175249 pmcid: 6107978
Zhuang, X. et al. The circadian clock components BMAL1 and REV-ERBalpha regulate flavivirus replication. Nat. Commun.10(1), 377 (2019).
pubmed: 30670689 pmcid: 6343007
Collier, D. A., Monit, C. & Gupta, R. K. The impact of HIV-1 drug escape on the global treatment landscape. Cell Host Microbe26(1), 48–60 (2019).
pubmed: 31295424
Bollinger, T. et al. Circadian clocks in mouse and human CD4+ T cells. PLoS ONE6(12), e29801 (2011).
pubmed: 22216357 pmcid: 3247291
Keller, M. et al. A circadian clock in macrophages controls inflammatory immune responses. Proc. Natl. Acad. Sci. U S A106(50), 21407–21412 (2009).
pubmed: 19955445 pmcid: 2795539
Kitchen, G. B. et al. The clock gene Bmal1 inhibits macrophage motility, phagocytosis, and impairs defense against pneumonia. Proc. Natl. Acad. Sci. U S A117(3), 1543–1551 (2020).
pubmed: 31900362 pmcid: 6983378
Taibi, D. M. Sleep disturbances in persons living with HIV. J. Assoc. Nurses AIDS Care24(1 Suppl), S72-85 (2013).
pubmed: 23290379 pmcid: 3543776
Baekken, M. et al. Association between HIV infection and attenuated diurnal blood pressure rhythm in untreated hypertensive individuals. HIV Med.10(1), 44–52 (2009).
pubmed: 19018875
Borkum, M. et al. Ambulatory blood pressure profiles in a subset of HIV-positive patients pre and post antiretroviral therapy. Cardiovasc. J. Afr.25(4), 153–157 (2014).
pubmed: 25192297 pmcid: 4170173
Kaczmarek, K., Morales, A. & Henderson, A. J. T cell transcription factors and their impact on HIV expression. Virology (Auckl)2013(4), 41–47 (2013).
Chang, C. C. et al. Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1. AIDS32(15), 2119–2128 (2018).
pubmed: 30005017 pmcid: 6173794
Raghuram, S. et al. Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta. Nat. Struct. Mol. Biol.14(12), 1207–1213 (2007).
pubmed: 18037887 pmcid: 2743565
Meng, Q. J. et al. Ligand modulation of REV-ERBalpha function resets the peripheral circadian clock in a phasic manner. J. Cell Sci.121(Pt 21), 3629–3635 (2008).
pubmed: 18946026 pmcid: 3069549
Solt, L. A. et al. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature485(7396), 62–68 (2012).
pubmed: 22460951 pmcid: 3343186
Trump, R. P. et al. Optimized chemical probes for REV-ERBalpha. J. Med. Chem.56(11), 4729–4737 (2013).
pubmed: 23656296 pmcid: 4347663
Kojetin, D. et al. Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB. ACS Chem. Biol.6(2), 131–134 (2011).
pubmed: 21043485
Aguilar-Cordova, E. et al. A sensitive reporter cell line for HIV-1 tat activity, HIV-1 inhibitors, and T cell activation effects. AIDS Res. Hum. Retrovir.10(3), 295–301 (1994).
pubmed: 8018390
Jeeninga, R. E. et al. Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. J. Virol.74(8), 3740–3751 (2000).
pubmed: 111883 pmcid: 111883
Liu, Y. et al. Structural and functional studies of CCAAT/enhancer binding sites within the human immunodeficiency virus type 1 subtype C LTR. Biomed. Pharmacother.64(10), 672–680 (2010).
pubmed: 20970301 pmcid: 2998390
Dickmeis, T. Glucocorticoids and the circadian clock. J. Endocrinol.200(1), 3–22 (2009).
pubmed: 18971218
Caratti, G. et al. REVERBa couples the circadian clock to hepatic glucocorticoid action. J. Clin. Invest.128(10), 4454–4471 (2018).
pubmed: 30179226 pmcid: 6160001
Cleret-Buhot, A. et al. Identification of novel HIV-1 dependency factors in primary CCR4(+)CCR6(+)Th17 cells via a genome-wide transcriptional approach. Retrovirology12, 102 (2015).
pubmed: 26654242 pmcid: 4676116
Dierickx, P. et al. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism. Proc. Natl. Acad. Sci. U S A116(25), 12147–12152 (2019).
pubmed: 31127047 pmcid: 6589768
Godfrey, C. et al. Global HIV antiretroviral drug resistance: a perspective and report of a national institute of allergy and infectious diseases consultation. J. Infect. Dis.216(suppl_9), S798–S800 (2017).
pubmed: 28973412 pmcid: 5853929
Deeks, S. G. HIV: shock and kill. Nature487(7408), 439–440 (2012).
pubmed: 22836995
Brown, S. A. et al. The period length of fibroblast circadian gene expression varies widely among human individuals. PLoS Biol.3(10), e338 (2005).
pubmed: 16167846 pmcid: 1233413
Buchrieser, J. et al. RIPK1 is a critical modulator of both tonic and TLR-responsive inflammatory and cell death pathways in human macrophage differentiation. Cell Death Dis.9(10), 973 (2018).
pubmed: 30250197 pmcid: 6155173
Dafinca, R. et al. C9orf72 hexanucleotide expansions are associated with altered endoplasmic reticulum calcium homeostasis and stress granule formation in induced pluripotent stem cell-derived neurons from patients with amyotrophic lateral sclerosis and frontotemporal dementia. Stem Cells34(8), 2063–2078 (2016).
pubmed: 27097283 pmcid: 4979662
De Mei, C. et al. Dual inhibition of REV-ERBbeta and autophagy as a novel pharmacological approach to induce cytotoxicity in cancer cells. Oncogene34(20), 2597–2608 (2015).
pubmed: 25023698
Hsu, M. et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. U S A100(12), 7271–7276 (2003).
pubmed: 12761383 pmcid: 165865
Crooks, G. E. et al. WebLogo: a sequence logo generator. Genome Res.14(6), 1188–1190 (2004).
pubmed: 15173120 pmcid: 419797
Khan, A. et al. JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. Nucl. Acids Res.46(D1), D1284 (2018).
pubmed: 29161433
Vermeire, J. et al. Quantification of reverse transcriptase activity by real-time PCR as a fast and accurate method for titration of HIV, lenti- and retroviral vectors. PLoS ONE7(12), e50859 (2012).
pubmed: 23227216 pmcid: 3515444
Fenton-May, A. E. et al. Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology10, 146 (2013).
pubmed: 24299076 pmcid: 3907080

Auteurs

Helene Borrmann (H)

Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.

Rhianna Davies (R)

Institute of Immunity and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.

Matthew Dickinson (M)

Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.

Isabela Pedroza-Pacheco (I)

Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.

Mirjam Schilling (M)

Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.

Alun Vaughan-Jackson (A)

Sir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK.

Andrea Magri (A)

Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.

William James (W)

Sir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK.

Peter Balfe (P)

Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.

Persephone Borrow (P)

Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.

Jane A McKeating (JA)

Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.

Xiaodong Zhuang (X)

Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK. xiaodong.zhuang@ndm.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH